12/4
07:30 am
trvi
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Low
Report
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
11/21
05:31 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/19
06:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/17
08:45 am
trvi
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
Low
Report
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
11/15
07:05 pm
trvi
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
Low
Report
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
11/15
04:40 am
trvi
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
11/14
04:18 pm
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
11/14
09:14 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/14
09:05 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/13
09:53 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.
11/6
04:36 pm
trvi
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 [Yahoo! Finance]
11/6
04:05 pm
trvi
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Neutral
Report
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
11/4
07:30 am
trvi
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Low
Report
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
10/8
07:51 am
trvi
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting [Yahoo! Finance]
10/8
07:30 am
trvi
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Low
Report
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
9/23
07:33 am
trvi
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut [Yahoo! Finance]
Medium
Report
Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut [Yahoo! Finance]
9/20
09:05 am
trvi
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025 [Yahoo! Finance]
Medium
Report
How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025 [Yahoo! Finance]
9/18
07:30 am
trvi
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Medium
Report
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
9/11
03:43 am
trvi
Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley [Yahoo! Finance]
Low
Report
Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley [Yahoo! Finance]